Spherium’s Cyclatop (SP14019), Safe and Efficacious for the Treatment of Atopic Dermatitis in Adults and Infants
The results of the clinical trial Cyclatop (NCT02865356) to investigate the safety, tolerability, pharmacokinetics and efficacy of SP14019 (Cyclosporine A 5% topical spray) across all group ages, for the treatment of mild to moderate atopic dermatitis, were presented today at the EADV Congress in Paris. SP14019 showed excellent safety and acceptability profile, clinically relevant and statistically significant efficacy with respect to placebo and very low systemic exposure to Cyclosporine A. - September 15, 2018
Spherium Biomed Starts Efficacy Trial Cyclatop for the Treatment of Atopic Dermatitis in Adults and Infants
The clinical trial is a pilot study (the Cyclatop study) for the evaluation of SP14019-F-01 topical solution for the treatment of atopic dermatitis. It is designed to investigate the safety, tolerability, pharmacokinetics and efficacy of SP14019-F-01 across all group ages for the treatment of mild... - September 29, 2016